Palleos, a contract research organization providing full-service clinical research solutions in Europe, today announced the successful completion of the Clinical Trial Application submission for a Phase 3 clinical trial of a novel treatment for moderate-to-severe chronic plaque-type psoriasis, sponsored by an Israeli pharmaceutical company. This achievement marks a significant milestone in bringing this promising therapy closer to patients
The study is designed to evaluate the efficacy and safety of the investigational therapy. Participants include male or female adults, aged 18 years and above, who will be screened across investigative centers in Eastern and Southern Europe. Patient recruitment is expected to begin shortly, with a planned enrollment of more than 200 patients in total.
Palleos is providing full-service support for the trial, managing all aspects of the study from preparing clinical trial design, regulatory and logistics support, project management, site initiation and monitoring through preparation of all final study documentation.
Interested in learning more about how Palleos’ CRO services can support your clinical trial needs? Contact us at info@palleos.com to discuss your project.
